Author: admin

GSK will support the who strategy to improve childrens health by expanding your medicine albendazole donations over the next 5 years.

|

GSK will support the who strategy to improve the health of children expand donations from your medicine albendazole during the next 5 years.

-GSK will increase the donation of albendazole for enabling the de-worming of school children in Africa

Spain, 2010-October during the presentation of the first report of the World Health Organization on the neglected tropical diseases, GSK has announced its new commitment for five years to expand the donation of your medicine albendazole for treating children at risk of spread of intestinal parasites, known as: worms transmitted overland (STH) (As soil-transmitted helminths).

The report confirms that the intestinal worms cause further health problems in school-age children than any other infection. (Transmitted by the earth worms) STHS exacerbate malnutrition and expand the types of anemia, this way hinder children’s physical growth and cognitive development that contributes significantly to the truancy. The lack of access to safe drinking water and adequate sanitation are major factors in the persistence and prevalence of these diseases.

As part of control programmes, who recommends annual treatment with albendazole in single dose (or mebendazole) to all children aged between 1 and 15 in STH endemic areas. This “Elimination of parasites” usually obtains immediate improvements in child health and development of children. Also reduces absenteeism at the school which leads to improved academic achievement and helps to reduce the problems on the already overburdened health systems.

Under the new compromise, GSK will increase the production capacity of albendazole through new investments in their factories in South Africa and the India. These investments will provide more than 400 million albendazole treatments additional to the current year. This represents a new and important contribution to the strategy of the United Nations to improve the health of women and children, and when combined with de-worming programmes, will allow countries to increase their efforts to achieve universal coverage of the school children in Africa. Shipments of the new donation of albendazole is expected to begin at the end of 2011.

Andrew Witty, CEO GlaxoSmithKline said: “the scale of what is needed to prevent and treat neglected tropical diseases means that it is essential to take an approach common. commend the leadership of who to increase the visibility of these diseases on the health community world.” There is a growing momentum in the industry, Governments and other institutions to provide both medicines and resources. Our activity in this area is widespread, with investigations ongoing in prevention and treatment. Another important commitment is now set to GSK and we hope to make a positive contribution in the improvement of the health of people living in countries faced with these diseases ”.

DRA. Margaret Chan, who Director-General has stated: “this commitment extends through a collaborative long-term between who and GSK in the fight against diseases that perpetuate poverty and keep people in poverty, especially in Africa.” Albendazole is a safe, effective and easy treatment administered to children infected with helminthiasis transmitted by the Earth, getting quick results with long-term benefits. GSK donation means that many millions of people (children) will benefit as part of a strategy that can break the cycle of poverty, poor health, poor school performance and loss of productivity. “

The new commitment to provide 400 million albendazole tablets a year for treatment of intestinal parasites joins the commitment of GSK’s who provide 600 million tablets of albendazole for use in the “ global programme for the Elimination of lymphatic Filiárisis ” a debilitating chronic illness that causes damage in the linfá system”Tico, kidneys, arms, legs and genitals. This means that the total donation of GSK to who will be 1000 million albendazole tablets to the year.

More info:

-Intestinal parasites affect more than 1.2 billion people around the world, 300 million of whom live in Africa.

-the biggest impact of intestinal parasites is vested in the children. For children aged 5-14 years in countries with limited resources, the intestinal worms represent 11-12 per cent of the total burden of disease in this group age.

-have intestinal parasites contributes to the malnutrition and slow growth. The anemia associated hookworms in women of childbearing age contributes significantly to low weight at birth and a greater mortality child.

-the schooling of children increases with de-worming programmes. 562 Million school children in the developing world, worm infections cause nearly 200 millions of years of schooling lost.

– there are three main species of intestinal worms, round worm (Ascaris lumbricoides), the whipworm (Trichuris trichiura) and the uncinarias (Necator americanus and Ancylostoma duodenale).

-neglected chronic diseases (NTDS) are a group of infections chronic disabling affecting populations más poor of the world and are an indicator of poverty and disadvantage. About 2.7 billion people living on less than $2 a day and it is estimated that 1.2 billion are affected by chronic illnesses neglected.

GlaxoSmithKline, is a world leading pharmaceutical company in the research and the health care committed to improving the quality of human life helping people do more, feel better and live longer.

Read More

Course in Tropical Medicine at the Prince of Asturias Hospital.

|

Course in Tropical Medicine at the Hospital Prince of Asturias.

the importance of health international

Spain, 2010-November Hospital Universitario Prince of Asturias, in Alcalá de Henares, hosted last week a new edition of the course Tropical Medicine and international health, to update knowledge on tropical diseases and international health with a multidisciplinary approach, it was directed to doctors, nurses and health care staff concerned in such diseases.

This course, which celebrates this year its eighth edition, was directed to the health personnel interested in diseases of the traveler and the immigrant or health cooperation in low-income countries. Migratory movements and the rise of international travel have increased the imported infections, as well as those that can get passengers during their journeys.

Within normal preparations for an international trip to risk areas must always be included basic precautions on hygiene, water consumption, bites of insects or contact with animals. In addition, travellers must remember that certain diseases are endemic in countries of Latin America or Africa and require a prior vaccination. “

“ We are very pleased with the reception that has this course between health professionals, because it helps to cover a part of the formative vacuum in this area of knowledge in the current of the majority of the Spanish universities teaching curricula and programs of rotation of the residents”explains Dr. Juan Cuadros, microbiology and Parasitology University Hospital service Prince of Asturias and coordinator of this course with Dr. Gerardo red, from the Servicio de Medicina Interna.

On the other hand, continues Juan Cuadros, “there is a growing demand for information in this field in the 3 area because nearly 20% of the population is immigrant and we practice one medicine global and well known endemic diseases in the countries of origin of the patients.” For example, almost all of the more than 30 cases of malaria this year we have served belong to the Group of African immigrants who visit relatives and friends in countries such as Equatorial Guinea, Nigeria and Senegal and not perform prophylactic ”.

New travellers

international cooperation has also created a profile of new travelers include aid, emergency and rescue groups, members of non-governmental organizations or diplomats who must maintain certain measures preventive health and hygiene.

Between the presentations of this course highlighted experiences in international cooperation as health aid after the earthquake in Haiti, the importance of the work of sanitation for the access to drinking water or the vector control of Chagas disease through the use of a painting with repellent of the vinchuca, the Bedbug that transmits the disease. In addition, there were clinical cases of diseases imported into immigrants, diseases transmitted by water and treatment of diseases such as malaria and leprosy.

Among the teachers of the course Tropical Medicine and international health include optional health centres in the community of Madrid, as hospitals Prince of Asturias, Carlos III, Hospital Ramon and Cajal, Fundación Jiménez Díaz, as well as members of various health agencies and cooperation. The course was the academic accreditation of the Laín Entralgo Agency and the patronage of the Foundation for the biomedical research of the Prince University Hospital of Asturias.

Read More

GlaxoSmithKline and Fiocruz extend their cooperation to research and develop new drugs for tropical diseases unknown.

|

GlaxoSmithKline and Fiocruz extend their cooperation to research and develop new drugs for tropical diseases unknown.

Spain, November 2010- GlaxoSmithKline and the Oswaldo Cruz Foundation (Fiocruz) have announced the expansion of its partnership to research and develop new drugs to treat diseases affecting the population of the countries most underdeveloped.

This new framework of collaboration is based on a relationship between Fiocruz and GlaxoSmithKline established in 1985 to make priority vaccines for the Brazilian public health, as well as those intended to immunize people against polio, Haemophilus influenzae type b (Hib), mumps, rubella, measles, rotavirus, and most recently, disease-related pneumonia. Furthermore, this relationship has also supported the development of research and manufacturing in Brazil through technology transfer and scientific collaboration.

The extension of the agreement between the two entities will allow scientists of Fiocruz and GSK’s Tres Cantos Madrid, sharing of research results, display new ideas and knowledge in areas such as Malaria, Tuberculosis, Chagas disease and Leishmaniasis. In this way, the agreement will focus on Chagas disease and Leishmaniasis due to the experience of Fiocruz in these diseases and the heavy burden of medical needs of people suffering from these diseases.

The new Alliance will be based on the strategy of open innovation of GSK, which aims to foster partnerships, offering access to the infrastructure, processes and the experience of the scientists working in Tres Cantos and Fiocruz.

As explained Dr. Nick Cammack, SVP and Head of the Tres Cantos Medicines Development Campus: “ in GSK are committed to collaboration in the search for new treatments for many diseases that affect millions of people in much of the world ”.

On the other hand, Fiocruz ’ s Vice President of Production and Innovation, Dr. Carlos Gadelha, pointed out that “ this agreement with Tres Cantos, Fiocruz will expand partnership with GSK with the aim of discovering and developing new drugs against unknown diseases. In this way, will meet the recognised experience of both institutions in an area of great impact on public health ”.

About GSK

Medicines development, Tres Cantos is dedicated to research and discovery of new drugs to combat diseases of countries in the process of developed. In January 2010, GSK set up the Lab Open Foundation non-profit. Open Lab Foundation was created to facilitate collaborations between schools and industry. GSK has made it possible that up to 60 scientists around the world have access to facilities of GSK in Tres Cantos. Also shared with external scientists – with funds from the Foundation Open Lab – skills, knowledge and infrastructure of the company, at the same time pursuing their own projects as part of an integrated team to discover new drugs.

On the Oswaldo Cruz Foundation (Fiocruz)

The Oswaldo Cruz Foundation (Fiocruz) was established on 25 may 1900, with the name of the Soroterapico Federal Institute. The Fiocruz mission was to combat the problems of public health of Brazil. For this reason, Fiocruz became an institution committed to the Brazilian reality and experimental medicine.

Promoting social development and health, develop and disseminate scientific and technological knowledge to be an agent of the citizenship, are concepts that have been linked to the Oswaldo Cruz Foundation with the Brazilian Ministry of health and the most important institutions of science and technology in health in Latin America.

Currently, Fiocruz is responsible for the development of research on the production of vaccines, drugs, reagents and kits for diagnosis. Their activity ranges from education and professional training, information and communication in health, science and technology; control of quality of products and services and the implementation of social programmes. It has more than 7,500 employees and professionals and researchers.

Read More

The PATH initiative for the vaccine against Malaria, MSD and the Langone of the University of New York Medical Center are collaborating in the investigation of a possible vaccine against malaria.

|

The initiative PATH for the vaccine against Malaria, MSD and the Langone of the University of New York Medical Center are collaborating in the investigation of a possible vaccine against the malaria

researchers try to block the activity of key proteins to prevent the malaria parasite in the liver

Bethesda, M.D., Whitehouse Station, N.J., New York, December of 2010. The development of a vaccine to prevent the malaria parasite is introduced in the human liver is the goal of a new partnership announced by world leaders in research and development of vaccines. The PATH initiative for vaccine against Malaria (MVI), MSD (known in the United States.)UU. (and Canada as Merck & Co) and the Centre medical Langone of the University of New York (NYU) collaborate to evaluate a strategy which takes a novel part of a major surface protein as diana in the malaria parasite. It is estimated that malaria is responsible for the deaths of nearly 900,000 people per year and that most of these relate to children under five in sub-Saharan Africa.

It was discovered that circumsporozoito (CSP) protein is a potential target in focus in the early stages of infection by malaria vaccine development. Researchers working in this project are focusing their efforts on a new strategy that has a region of the CSP that is important for a critical function of the protein as diana. It is expected that blocking this function, it can prevent liver invasion by the parasite, which is an essential phase that causes the disease of malaria.

“ Believe that we can improve the way in which vaccines are designed virosome strategically addressing this very important protein function ”, indicated the DRA. Elizabeth Nardin, Professor of the Department of medical parasitology in the NYU Langone Medical Center. “ Other approaches to get directed to the CSP vaccine have required extremely high antibody levels, and they are difficult to obtain and maintain. “This approach has the potential to remedy this problem.”

The justification for this targeted strategy of “ conjugate of peptides and proteins ” is based on the knowledge of the technology of vaccines to be used in the determination of a specific protein of malaria is known to cause an immune response. It has already shown that the CPS has an important protective efficacy in practice, in the context of the RTS, S vaccine most advanced candidate who is currently in a phase III clinical trial. In addition, MSD has included other vaccines based on conjugate that they have been developed against bacterial pathogens in pediatric vaccines approved and widely used.

“ History has shown that the vaccines can be a powerful tool against diseases, ” stated Dr. John Shiver, Vice President of discovery of vaccines of MSD. “ agree that the new methods and consortia, as this collaboration with MVI and the NYU Langone Medical Center, they are important to continue to innovate in the battle against the malaria parasite ”.

“ With the availability of a first generation malaria vaccine in perspective, we are increasing our efforts to find and fund scientific approaches for malaria vaccines that have the potential to be more efficient and protect more people ” explained Dr. Christian Loucq, director of MVI. “ we are very pleased that one of the largest pharmaceutical laboratories in the world and a Center medical academic have undertaken to test a promising new way to protect children from malaria ”.

Although this vaccine is being tested primarily for use in children under the age of one year, could be used to prevent disease in vulnerable to Plasmodium falciparum, the deadliest species of parasite, and potentially could be adapted to also prevent P. vivax. Approximately 40% of the world’s population living at risk of contracting malaria because of p. vivax or p. falciparum.

“ Though it is still quite early, we are delighted to have the opportunity to explore the promise of this innovative vaccine with MSD and MVI ”, noted Dr. Photini Sinnis, adjunct professor in medical parasitology in Center doctor Langone of the NYU.

On the PATH initiative for vaccine against Malaria (MVI)

The PATH initiative for the vaccine against Malaria (MVI) is a program on a global scale PATH established in 1999 with an initial grant from the Bill & Melinda Gates Foundation. MIV mission is to accelerate the development of malaria vaccines and ensure their availability and accessibility in developing countries. MVI vision is to achieve a world free of malaria.

On PATH

PATH is an international non-profit which creates solutions sustainable, culturally relevant, thus enabling communities worldwide to ending cycles of long-term ill-health. Through collaboration with various public and private sector institutions, PATH helps provide appropriate vital strategies that change the way in which people thinks and acts and health technology. The work of PATH improves the health and well-being around the world.

On the NYU Langone Medical Center

The Langone medical center of NYU , an academic medical center integrated global quality focused on patients, is one of the main centres of the United States.UU. for excellence in health care, biomedical research and medical education. Located in Midtown Manhattan, the NYU Langone Medical Center consists of three hospitals – Tisch Hospital, a tertiary facility in intensive care with 705 beds; the Institute of Medicine of rehabilitation Rusk, the first rehabilitation hospital in the world, with 174 beds and extensive programmes of rehabilitation for patients travelling, and the Hospital for diseases of the joints, there are 190 beds and it is one of the five hospitals in the world dedicated to the trauma and the Rheumatology – in addition to the Faculty of Medicine of the University of New York, one of the most prominent academic institutions of EE.U.S.

About MSD

now MSD is a leader in global health who works to contribute to global health. MSD is known as Merck in United States and Canada. Through our medicines, vaccines, biological therapies and consumption and veterinary products, we work with our clients operating in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increase access to health care through programmes of long range that they donate and deliver our products to the people who need it.

Read More

Malaria affects 2,850 million people around the world already.

|

Malaria already affects 2,850 million people around the world.

Spain, 2011-February global vaccination campaign against malaria. The SciNet Corporation is distributing medical emergency and units of mass vaccination, as well as other specialities like ophthalmology, dentistry, obstetrics and electromedical.

Emergency medical units have everything you need to operate with autonomy even in places that lack of any infrastructure. In addition to responding to medical emergencies, these containers serve specialties such as electromedical equipment, ophthalmology, dentistry and obstetrics. Also, include a module with machine vending supplying consumable sanitary serum, syringes, tweezers, pharmaceutical materials, etc.

These units will be complemented by mini-plantas of production, which are fully equipped containers to provide all kinds of products and services: food, drinking water, shoes, clothes, etc. As well as emergency medical units, each container includes machines, cables, pipes and facilities required to operate with autonomy.

Also distributed more than 2,000,000 through digital certificates ‘ chipless ’ radio frequency (RFID), being provided to over 20 million during the next six months. Devices ‘ chipless ’ are being distributed in developing countries and regions of the world of high risk, as well as natural disasters and can be used immediately for the acquisition of all kinds of first necessity products produced by the Mini-plantas (drinking water, bread, dehydrated foods)(, medicines and medical supplies, dairy products, etc.).

Malaria Atlas Project
SciNet Corporation
SCINETCORP Foundation

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips